121 related articles for article (PubMed ID: 25873167)
21. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.
Murai MJ; Pollock J; He S; Miao H; Purohit T; Yokom A; Hess JL; Muntean AG; Grembecka J; Cierpicki T
Blood; 2014 Dec; 124(25):3730-7. PubMed ID: 25305204
[TBL] [Abstract][Full Text] [Related]
22. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).
Borkin D; Pollock J; Kempinska K; Purohit T; Li X; Wen B; Zhao T; Miao H; Shukla S; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2016 Feb; 59(3):892-913. PubMed ID: 26744767
[TBL] [Abstract][Full Text] [Related]
23. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract][Full Text] [Related]
24. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
Borkin D; Klossowski S; Pollock J; Miao H; Linhares BM; Kempinska K; Jin Z; Purohit T; Wen B; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2018 Jun; 61(11):4832-4850. PubMed ID: 29738674
[TBL] [Abstract][Full Text] [Related]
25. Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia.
Lin TL; Jaiswal AK; Ritter AJ; Reppas J; Tran TM; Neeb ZT; Katzman S; Thaxton ML; Cohen A; Sanford JR; Rao DS
Blood Adv; 2024 Jan; 8(2):261-275. PubMed ID: 38048400
[TBL] [Abstract][Full Text] [Related]
26. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
[TBL] [Abstract][Full Text] [Related]
27. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong
Xu S; Aguilar A; Huang L; Xu T; Zheng K; McEachern D; Przybranowski S; Foster C; Zawacki K; Liu Z; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2020 May; 63(9):4997-5010. PubMed ID: 32338903
[TBL] [Abstract][Full Text] [Related]
28. [Interaction between mixed-lineage leukemia and Menin proteins].
Liu L; Li BS; Ye QD; He YY; Tang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1130-4. PubMed ID: 19840436
[TBL] [Abstract][Full Text] [Related]
29. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.
He S; Senter TJ; Pollock J; Han C; Upadhyay SK; Purohit T; Gogliotti RD; Lindsley CW; Cierpicki T; Stauffer SR; Grembecka J
J Med Chem; 2014 Feb; 57(4):1543-56. PubMed ID: 24472025
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups.
Lei H; Zhang SQ; Bai H; Zhao HY; Sun J; Chuai H; Xin M
J Med Chem; 2022 Oct; 65(19):13413-13435. PubMed ID: 36173787
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors.
Bai H; Yang Z; Lei H; Wu Y; Liu J; Yuan B; Ma M; Gao L; Zhang SQ; Xin M
Eur J Med Chem; 2024 Mar; 268():116226. PubMed ID: 38367493
[TBL] [Abstract][Full Text] [Related]
32. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
[TBL] [Abstract][Full Text] [Related]
33. Covalent and noncovalent constraints yield a figure eight-like conformation of a peptide inhibiting the menin-MLL interaction.
Fortuna P; Linhares BM; Purohit T; Pollock J; Cierpicki T; Grembecka J; Berlicki Ł
Eur J Med Chem; 2020 Dec; 207():112748. PubMed ID: 32882610
[TBL] [Abstract][Full Text] [Related]
34. Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility.
Senter T; Gogliotti RD; Han C; Locuson CW; Morrison R; Daniels JS; Cierpicki T; Grembecka J; Lindsley CW; Stauffer SR
Bioorg Med Chem Lett; 2015 Jul; 25(13):2720-5. PubMed ID: 25987377
[TBL] [Abstract][Full Text] [Related]
35. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
[TBL] [Abstract][Full Text] [Related]
36. Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner.
He S; Malik B; Borkin D; Miao H; Shukla S; Kempinska K; Purohit T; Wang J; Chen L; Parkin B; Malek SN; Danet-Desnoyers G; Muntean AG; Cierpicki T; Grembecka J
Leukemia; 2016 Feb; 30(2):508-13. PubMed ID: 26084867
[No Abstract] [Full Text] [Related]
37. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction.
Zhou H; Liu L; Huang J; Bernard D; Karatas H; Navarro A; Lei M; Wang S
J Med Chem; 2013 Feb; 56(3):1113-23. PubMed ID: 23244744
[TBL] [Abstract][Full Text] [Related]
39. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
40. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
